Xenon Pharmaceuticals Statistics
Share Statistics
Xenon Pharmaceuticals has 76.73M
shares outstanding. The number of shares has increased by 1.42%
in one year.
| Shares Outstanding | 76.73M |
| Shares Change (YoY) | 1.42% |
| Shares Change (QoQ) | 0.4% |
| Owned by Institutions (%) | 97.9% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,667 |
| FTD / Avg. Volume | 1.03% |
Short Selling Information
The latest short interest is 3.58M, so 4.68% of the outstanding
shares have been sold short.
| Short Interest | 3.58M |
| Short % of Shares Out | 4.68% |
| Short % of Float | 5.22% |
| Short Ratio (days to cover) | 4.95 |
Valuation Ratios
The PE ratio is -13.03 and the forward
PE ratio is -6.55.
Xenon Pharmaceuticals's PEG ratio is
-1.27.
| PE Ratio | -13.03 |
| Forward PE | -6.55 |
| PS Ratio | 0 |
| Forward PS | 3.1 |
| PB Ratio | 4.04 |
| P/FCF Ratio | -16.55 |
| PEG Ratio | -1.27 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Xenon Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.85,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.85 |
| Quick Ratio | 17.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-741,550.63 |
| Employee Count | 316 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.09M |
| Effective Tax Rate | 1.72% |
Stock Price Statistics
The stock price has increased by -26.4% in the
last 52 weeks. The beta is 1.22, so Xenon Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.22 |
| 52-Week Price Change | -26.4% |
| 50-Day Moving Average | 34.6 |
| 200-Day Moving Average | 38.94 |
| Relative Strength Index (RSI) | 31.98 |
| Average Volume (20 Days) | 844,310 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -279.3M |
| Net Income | -234.33M |
| EBITDA | -235.86M |
| EBIT | -238.42M |
| Earnings Per Share (EPS) | -3.01 |
Full Income StatementBalance Sheet
The company has 142.71M in cash and 9.02M in
debt, giving a net cash position of 133.7M.
| Cash & Cash Equivalents | 142.71M |
| Total Debt | 9.02M |
| Net Cash | 133.7M |
| Retained Earnings | -899.47M |
| Total Assets | 798.14M |
| Working Capital | 599.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -181.39M
and capital expenditures -3.08M, giving a free cash flow of -184.46M.
| Operating Cash Flow | -181.39M |
| Capital Expenditures | -3.08M |
| Free Cash Flow | -184.46M |
| FCF Per Share | -2.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
